Valneva grants license to Immune Targeting Systems for the development of hepatitis B vaccine
France-based biotech firm Valneva (EPA: VLA) and UK company Immune Targeting Systems (ITS) have signed an exclusive worldwide commercial license agreement, granting ITS rights to research, develop and commercialize hepatitis B vaccine candidates in combination with Valneva’s IC31 Adjuvant.
Financial terms of the accord were not disclosed but include an upfront payment. If successful, product candidates from these agreements may lead to additional cash payments for achieved milestones along with future royalties on net sales.
Thomas Lingelbach, president and chief executive and Franck Grimaud, president and chief business officer of Valneva, commented: “Hepatitis B is a virulent and contagious disease and we are excited to license our IC31 vaccine Adjuvant to Immune Targeting Systems for developing a potential novel vaccine.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze